Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic)

Abstract Background Lupus animal model has shown that arsenic trioxide (ATO), a treatment of acute promyelocytic leukaemia, could be effective in SLE. This is the first clinical study to determine the safety and efficacy of a short course of intravenous ATO in patients with active SLE. Methods This...

Descripció completa

Dades bibliogràfiques

Autors principals:	Mohamed Hamidou, Antoine Néel, Joel Poupon, Zahir Amoura, Mikael Ebbo, Jean Sibilia, Jean-Francois Viallard, Benjamin Gaborit, Christelle Volteau, Jean Benoit Hardouin, Eric Hachulla, François Rieger
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2021-03-01
Col·lecció:	Arthritis Research & Therapy
Matèries:	Systemic lupus erythematosus Autoimmune diseases Treatment Arsenic trioxide Phase II clinical trial
Accés en línia:	https://doi.org/10.1186/s13075-021-02454-6
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!